Company Overview

Theravance Biopharma, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of organ‑selective medicines for respiratory and pulmonary diseases. The company operates within the biotechnology and specialty pharmaceuticals industries, with an emphasis on treatments for chronic lung conditions such as chronic obstructive pulmonary disease (COPD) and other respiratory disorders. Its business model combines internal research and development with strategic partnerships to advance and monetize late‑stage assets.

The company’s primary value drivers have historically included royalty‑based revenue from marketed respiratory therapies and the advancement of a targeted clinical pipeline. Theravance Biopharma was founded in 1996 and originally operated as part of a broader Theravance entity before undergoing a series of strategic separations and asset divestitures between 2014 and 2022. These transactions reshaped the company into a more focused organization centered on pulmonary and organ‑selective pharmacology.

Business Operations

Theravance Biopharma generates revenue primarily through royalty and collaboration income rather than direct commercial sales. A key historical revenue source has been royalties associated with YUPELRI® (revefenacin), a once‑daily nebulized long‑acting muscarinic antagonist for COPD, which is commercialized by Viatris Inc. following the transfer of commercialization rights. In 2022, Theravance Biopharma sold a substantial portion of its future YUPELRI royalties to Royalty Pharma plc, significantly altering its revenue profile.

Operationally, the company focuses on clinical development activities, regulatory strategy, and lifecycle management of its remaining pipeline assets. Its research capabilities emphasize organ‑targeted drug design intended to maximize efficacy while limiting systemic exposure. Theravance Biopharma does not maintain large‑scale manufacturing operations and relies on third‑party partners and contract research organizations for development and production activities.

Strategic Position & Investments

The company’s strategic direction is centered on advancing a focused late‑stage pipeline in respiratory and related disorders while maintaining capital discipline following its royalty monetization transactions. A notable strategic move was the divestiture of its Theravance Biopharma Ireland operations and the separation of commercial infrastructure, allowing management to concentrate on development‑stage assets with differentiated mechanisms of action.

Theravance Biopharma has also pursued value realization through asset sales and licensing rather than broad diversification. Prior investments included the development of ampreloxetine for neurogenic orthostatic hypotension, which was later partnered and transferred. As of the most recent public disclosures, the company positions itself as a streamlined R&D organization with optionality for future partnerships, acquisitions, or additional asset monetization tied to clinical milestones.

Geographic Footprint

Theravance Biopharma is headquartered in the United States, with its principal executive offices located in South San Francisco, California. Its operations are primarily U.S.‑based, reflecting its focus on research, clinical development, and corporate management rather than global manufacturing or direct sales.

International exposure is indirect and largely tied to partnerships and licensing arrangements. Through collaborators such as Viatris, the company’s products and intellectual property have commercial reach across North America, Europe, and other global markets, though Theravance Biopharma itself maintains a limited physical presence outside the United States.

Leadership & Governance

Theravance Biopharma is led by an executive team with experience in biotechnology strategy, respiratory medicine, and capital markets. The company was co‑founded by Glenn Cooper, who played a central role in shaping its organ‑selective drug discovery platform and long‑term strategic vision. Current leadership emphasizes portfolio focus, disciplined capital allocation, and partnership‑driven value creation.

Key executives include:

• Rick E. Winningham – Chief Executive Officer
• Michael A. Wyzga – Chief Financial Officer
• Carol A. Collins – Chief Legal Officer and Corporate Secretary

The leadership team and board of directors oversee governance with an emphasis on shareholder value, regulatory compliance, and strategic flexibility, particularly following the company’s transition away from recurring royalty income toward a development‑focused model.